Business
Nuvalent Appoints Emily Drabant Conley, PhD, to Board of Directors
Industry-leading genomics expertise supports Nuvalent's advancement as a clinical-stage precision oncology company CAMBRIDGE, Mass., Feb. 3, 2022 /PRNewswire/
About this update from Nuvalent, Inc.
[{"type":"text","content":"Industry-leading genomics expertise supports Nuvalent's advancement as a clinical-stage precision oncology company\n\n\nCAMBRIDGE, Mass., Feb. 3, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Emily Drabant Conley, Ph.D., Chief Executive Officer of Federation Bio, to its Board of Directors.\n\n \n \n \n \n \n \n\n \n\"I'm impressed by Nuvalent's focus on compelling science and only advancing opportunities with best-in-class potential, both of which I believe position the company to deliver on their goal of new therapies that may help physicians and their patients stay one step ahead of cancer,\" said Dr. Conley. \"Additionally, I look for authenticity as a hallmark of strong leadership and am inspired to have found this clearly in CEO Jim Porter and the cultural foundation at Nuvalent.\"\nDr. Conley's work has contributed to industry-shaping advances in genomics that empower patients and clinicians with actionable health data. Prior to joining Federation Bio, she spent over a decade at 23andMe where, as Vice President of Business Development, she was instrumental in powering the company's growth from 30 employees into a household name.\n\"Dr. Conley's depth of experience in diagnostics and genomics is a natural complement to our focus on therapeutic targets that are oncogenic drivers as we move into the next phase of our journey as a clinical-stage company,\" said James Porter, Ph.D., Chief Executive Officer at Nuvalent. \"We are honored to grow our board with her unique perspective encompassing the development of both cutting-edge diagnostics and oncology therapeutics, and her passion for realizing a future where these tools represent the standard of care for all patients.\"\nNuvalent is currently enrolling patients in the Phase 1 portion of its ARROS-1 study, a Phase 1/2 clinical trial evaluating its lead candidate NVL-520, a ROS1-selective inhibitor, in patients with advanced ROS1-positive non-small cell lung cancer and other solid tumors. A clinical trial for its parallel lead candidate NVL-655, an ALK-selective inhibitor, is expected to be initiated in the first half of 2022. NVL-520 and NVL-655 are designed with the aim to address the clinical challenges of emergent treatment...